retatrutide triple agonist Retatrutide: The first-in-class investigational receptor redefining Type 2 diabetes therapy Retatrutide — Triple Agonist (GIP/GLP-1/Glucagon)
Pay in 4 interest-free payments of $6.35 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5























